减肥药概念股上涨，礼来涨超5%，股价再创新高；安进涨超3%，罗氏涨2.4%，诺和诺德涨1.9%。消息面上，诺和诺德近日已在美国正式推出全球首款用于成人减重的GLP-1口服药。此外，有消息称礼来就拟以超过10亿美元收购Ventyx Biosciences的交易进行深入谈判，后者的一种实验性药物目前正在中期开发阶段，用于治疗与肥胖相关的心血管疾病。(格隆汇)
减肥药概念股上涨，礼来涨超5%，股价再创新高；安进涨超3%，罗氏涨2.4%，诺和诺德涨1.9%。消息面上，诺和诺德近日已在美国正式推出全球首款用于成人减重的GLP-1口服药。此外，有消息称礼来就拟以超过10亿美元收购Ventyx Biosciences的交易进行深入谈判，后者的一种实验性药物目前正在中期开发阶段，用于治疗与肥胖相关的心血管疾病。(格隆汇)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.